Mississippi Department Human Services  
Division of Youth Services

Asthma Management Flow Sheet

Student Name: ___________________________ DOB: ___________________________ Living Unit: ___________________________

Does the Student have: Spacer? ___ Personal best peak flow? ___ Date measured: ___________________________

### Date of Encounter

**Encounter Type:**  
- R = Routine, O = Office Visit,  
- ER = Emergency Room, H = Hospitalization

**NAEPP Severity Level:**  
- I = Mild Intermittent, P Mild = Mild Persistent, P Mod = Moderate Persistent, P Sev = Severe Persistent

### Peak Flow:

**Medications:** Fill in medication/dose: RX = Prescribed C = Continued, D = Dose Change D/C = Discontinued

- * Short-acting beta-agonist:
- * Inhaled Corticosteroid:
- * Cromolyn/Nedocromil:
- * Leukotriene modifier:
- * Long-acting beta-agonist:
- * Methylxanthine:
- * Systemic corticosteroid:
- * Other:

Influenza vaccine administered:

Asthma action plan reviewed with student:

### NAEPP Severity Level Classifications:

<table>
<thead>
<tr>
<th>Level</th>
<th>Symptoms</th>
<th>Clinical Features before Treatment Nighttime symptoms</th>
<th>Lung Function</th>
</tr>
</thead>
</table>
| **Step 1** Mild Intermittent | ➢ Symptoms 2 times a week  
➢ Asymptomatic and normal PEF between exacerbations | > 2 times a month                                     | ➢ FEV, or PEF > 80% Predicted  
➢ PEF variability < 20% |
| **Step 2** Mild Persistent    | ➢ Symptoms > 2 times a week but > 1 time a day, exacerbations may affect activity | > 2 times a month                                     | ➢ FEV, or PEF > 60% Predicted  
➢ PEF variability < 30% |
| **Step 3** Moderate Persistent | ➢ Daily symptoms  
➢ Daily use of inhaled short-acting beta agonist  
➢ Exacerbations affect activity  
➢ Exacerbations > 2 times a week; may last days | > 1 time a week                                      | ➢ FEV, or PEF > 60% - <80%Predicted  
➢ PEF variability < 30% |
| **Step 4** Severe Persistent      | ➢ Continual symptoms  
➢ Limited physical activity  
➢ Frequent exacerbations | Frequent                                                | ➢ FEV, or PEF < 60% Predicted  
➢ PEF variability > 30% |

Form XI.20.C  
Effective Date: 07/09/07  
Page 1 of 1